Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Jasper Therapeutics, Inc. - Class A Common Stock (NQ:JSPR)

1.950 +0.140 (+7.73%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Jasper Therapeutics, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Jasper Therapeutics Shares Jump After Positive Data From Sickle Cell Disease Trial
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
5 Value Stocks In The Healthcare Sector
 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Why Hoth Therapeutics Shares Are Trading Higher By More Than 130%? Here Are 60 Stocks Moving In Thursday's Mid-Day Session
Gainers Hoth Therapeutics, Inc. (NASDAQ: HOTH) shares jumped 131.5% to $10.19 after the FDA accepted the IND application for HT-001. 
Via Benzinga
Jasper Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
From Jasper Therapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
Upgrades 
Via Benzinga
Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary
 
Via Benzinga
Jasper Shares Climb As FDA Grants Fast Track Status To Immunodeficiency Disease Candidate
Jasper Therapeutics (NASDAQ: JSPR) announced that its lead asset JSP191 has received fast track designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients with severe... 
Via Benzinga
Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday
Gainers Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
  
Via Benzinga
Mosaic Tumbles Around 10%, Here's 71 Biggest Movers From Yesterday
Gainers Fujian Blue Hat Interactive Entertainment Technology Ltd. (NASDAQ: BHAT) shares jumped 263% to $2.73 on Thursday. Blue Hat Interactive terminated its previously proposed shelf takedown... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Jasper Therapeutics Reveals Treatment of First Patient in the Phase 1/2 Study of JPS191 for Fanconi Anemia
Jasper Therapeutics, Inc. (NASDAQ: JSPR) dosed first patient in the Phase 1/2 clinical study of its drug candidate JPS191 as a conditioning agent in the treatment of Fanconi Anemia. 
Via Benzinga
66 Biggest Movers From Yesterday
Gainers Better Therapeutics, Inc. (NASDAQ: BTTX) shares surged 120.4% to close at $2.01 on Monday following a 5% drop on Friday. SoundHound AI, Inc. (NASDAQ: SOUN) shares surged... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Ocular Therapeutix (NASDAQ:OCUL) shares moved upwards by 12.3% to $4.01 during Friday's after-market session. The company's market cap stands at $307.7 million. 
Via Benzinga
Jasper Therapeutics Presented Updated Data from Phase 1 Clinical Trial of JSP191
Jasper Therapeutics, Inc., (NASDAQ: JSPR) announced updated efficacy, safety and pharmacokinetic data from its Phase 1 clinical trial of JSP191, in older patients with myelodysplastic syndromes (MDS)... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Statera BioPharma (NASDAQ:STAB) stock rose 23.6% to $0.9 during Friday's pre-market session. The company's market cap stands at $32.4 million. InVivo... 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 236 companies hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 90 companies set new 52-week lows. Areas of Significance In Today's 52-Week Lows: The company with the largest market cap to set a new 52-week low was... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 107 companies set new 52-week lows. Points of Interest From Today's 52-Week Lows: Citigroup (NYSE:C) was the largest company by... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2022
Upgrades According to DA Davidson, the prior rating for Envestnet Inc (NYSE:ENV) was changed from Neutral to Buy. In the fourth quarter, Envestnet showed an EPS of $0.50, compared... 
Via Benzinga
Mid-Day Market Update: Crude Oil Down 1%; Inspira Technologies Shares Spike Higher
Midway through trading Thursday, the Dow traded down 0.18% to 35,691.63 while the NASDAQ fell 0.72% to 15,672.75. The S&P also fell, dropping 0.37% to 4,683.86. The U.S. has... 
Via Benzinga
Topics Stocks
Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2021
Upgrades For Nektar Therapeutics (NASDAQ: 
Via Benzinga
52 Biggest Movers From Yesterday
Gainers ION Geophysical Corporation (NYSE: IO) shares surged 29.8% to settle at $0.5969. Synaptogenix, Inc. (NASDAQ: SNPX) climbed 29.4% to close at $10.09. Synaptogenix... 
Via Benzinga
52 Weeks High And Low Article
Stocks that Broke Yearly Lows Tuesday Morning During Tuesday's morning trading, 87 companies set new 52-week lows. Noteworthy Highlights From Today's 52-Week Highs And Lows: 10x... 
Via Benzinga
56 Biggest Movers From Yesterday
Gainers Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) shares jumped 84% to close at $4.95 on Thursday after the company signed an exclusive summary distribution agreement... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.